Granular Hydroxypropyl Methylcellulose for Direct Compression

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing pharmaceutical dosage forms with small particle-sized hydroxypropyl methylcellulose exhibit poor flowability and increased risk of dust inhalation or explosions, while conventional granulation processes are complex and unsuitable for moisture or heat-sensitive active ingredients.

Innovation Solution

A granular material with a mean particle diameter of 150 to 350 micrometers, composed of hydroxypropyl methyl cellulose with specific substitution levels, is produced through fluid bed granulation, offering improved flowability, compactibility, and sustained release properties, suitable for direct compression processes.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Duration of action of moving object

If fine particle sized hydroxypropyl methylcellulose is used to achieve sustained release, then release profile is improved, but flowability deteriorates and dust risk increases

Engineering Contradiction:
Improverelease profileVSAvoidflowability
Core Design Contradiction:
Duration of action of moving objectVSEase of operation

Solution Approach 1:

The patent applies segmentation by dividing the fine particles into granulated forms with a broader particle size distribution (D10: 45-75 μm, D50: 106-150 μm, D90: 212-300 μm). This segmentation into different size ranges improves flowability while maintaining the sustained release capability through the fine particle component

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent changes the particle size parameter from uniform fine particles to a distributed size range through granulation. The granulated material has D50 of 106-150 μm compared to the original fine particles that passed through 100-140 mesh screens, optimizing both flowability and release characteristics

Inventive Principle:
Principle #35Parameter changes

2Ease of operation

If conventional wet granulation processes are used to improve flowability, then flow properties are improved, but process complexity and moisture/heat exposure increase

Engineering Contradiction:
Improveflow propertiesVSAvoidprocess complexity
Core Design Contradiction:
Ease of operationVSDevice complexity

Solution Approach 1:

The patent extracts the granulation step from the complex wet granulation process, using only minimal water (0.5-5% w/w) as binding agent without the need for drying and milling steps. This takes out the problematic elements of wet granulation while retaining the flowability benefits

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The patent uses minimal water as a temporary binding agent that is easily removed, replacing the complex multi-step wet granulation process with a simple granulation step followed by minimal drying, reducing process complexity and equipment requirements

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

3Device complexity

If direct compression is used to simplify the process, then process simplicity is improved, but material flowability and compactibility requirements become more stringent

Engineering Contradiction:
Improveprocess simplicityVSAvoidmaterial properties requirements
Core Design Contradiction:
Device complexityVSManufacturing precision

Solution Approach 1:

The patent applies preliminary action by granulating the hydroxypropyl methylcellulose before direct compression to create material with optimal flow and compactibility properties. This preliminary granulation step prepares the material to meet the stringent requirements of direct compression

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The patent changes the material parameters through granulation, achieving D50 of 106-150 μm and specific flowability characteristics (angle of repose 25-35°) that enable successful direct compression with standard equipment

Inventive Principle:
Principle #35Parameter changes

4Object-affected harmful factors

If dry granulation processes are used to avoid moisture, then moisture sensitivity is addressed, but process complexity and milling requirements increase

Engineering Contradiction:
Improvemoisture sensitivityVSAvoidmilling scheme complexity
Core Design Contradiction:
Object-affected harmful factorsVSDevice complexity

Solution Approach 1:

The patent uses minimal water (0.5-5% w/w) as a temporary binding agent during granulation that is easily removed by simple drying, avoiding the need for complex dry granulation milling schemes while still protecting moisture-sensitive materials

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The granular material ensures strong, hard tablets with consistent physical properties and reproducible sustained release kinetics, reducing tablet-to-tablet variability and eliminating the need for complex granulation processes, while maintaining effective drug release profiles.

Implementation Method 1

The granular material is produced through fluid bed granulation

Methodology Applied
Scientific EffectFluidization: Fluidisation

Data Source

PatentEP2146696B1Granular material for dosage forms
Publication Date: 2020.01.22 DOW GLOBAL TECHNOLOGIES LLC
  • EP2146696B1 patent drawingFigure 1
  • EP2146696B1 patent drawingFigure 2
  • EP2146696B1 patent drawingFigure 3

AI summary

A granular material which has a mean particle diameter of 150 to 800 micrometers; and an unsettled bulk density of 0.1 to 0.35 g/cm3 and/or a compactibility which results in a compact with a tensile strength of at least 1.7 MPa when the granular material is subjected to a compaction pressure of 266 MPa; and wherein the main component of the granular material is a cellulose derivative or an alkylene oxide homo- or copolymer or a blend thereof is useful for preparing dosage forms with a controlled release profile.